Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Syngene International Limited
  6. News
  7. Summary
    539268   INE398R01022

SYNGENE INTERNATIONAL LIMITED

(539268)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dyadic International, Inc. Enters into Collaboration with Syngene International Limited

05/26/2021 | 08:30am EDT

Dyadic International, Inc. announced that the Company has entered into a collaboration with Syngene International Limited, to develop a COVID-19 vaccine candidate that can protect against the emerging variants of concern and which can be manufactured affordably, at very large scale, using Dyadic’s proprietary C1-cell protein production platform. Like the expanded partnership previously announced with Medytox, Inc., to co-develop vaccines in the Republic of Korea and multiple Southeast Asian countries, Dyadic will work with Syngene to develop a vaccine candidate to immunize people against current and future variants of the COVID-19 virus.


© S&P Capital IQ 2021
All news about SYNGENE INTERNATIONAL LIMITED
07/20SYNGENE INTERNATIONAL : Consolidated Net Profit Climbs in Fiscal Q1
MT
07/20Syngene International Limited Announces Resignation of John M M Shaw from the Board of ..
CI
07/20Syngene International Limited Reports Earnings Results for the First Quarter Ended June..
CI
06/22Syngene International Limited Appoints Dr. Kush Parmar as an Additional Director (Indep..
CI
05/26DYADIC INTERNATIONAL : Syngene to Join Forces for COVID-19 Vaccine Production
MT
05/26SYNGENE INTERNATIONAL : Dyadic announces development of COVID-19 Vaccine in India
AQ
05/26Dyadic International, Inc. Enters into Collaboration with Syngene International Limited
CI
04/28BIOCON : Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surge..
RE
04/28SYNGENE INTERNATIONAL : Posts Higher Profit in January-March
MT
04/27Syngene International Limited Reports Earnings Results for the Fourth Quarter Ended Mar..
CI
More news
Financials
Sales 2022 25 547 M 341 M 341 M
Net income 2022 4 365 M 58,3 M 58,3 M
Net cash 2022 4 104 M 54,9 M 54,9 M
P/E ratio 2022 55,5x
Yield 2022 0,08%
Capitalization 240 B 3 213 M 3 214 M
EV / Sales 2022 9,25x
EV / Sales 2023 7,74x
Nbr of Employees 5 437
Free-Float 28,7%
Chart SYNGENE INTERNATIONAL LIMITED
Duration : Period :
Syngene International Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNGENE INTERNATIONAL LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 606,45 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jonathan Hunt Chief Executive Officer, MD & Executive Director
Sibaji Biswas Chief Financial Officer
Kiran Mazumdar-Shaw Non-Executive Chairman
Mahesh K Bhalgat Chief Operating Officer
Priyadarshini I. Mahapatra Secretary & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
SYNGENE INTERNATIONAL LIMITED-5.18%3 225
MODERNA, INC.219.34%134 660
LONZA GROUP AG27.07%58 240
IQVIA HOLDINGS INC.38.99%47 715
SEAGEN INC.-0.54%31 691
CELLTRION, INC.-39.00%25 332